<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2649">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04478071</url>
  </required_header>
  <id_info>
    <org_study_id>HSC-MS-20-0395</org_study_id>
    <nct_id>NCT04478071</nct_id>
  </id_info>
  <brief_title>Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)</brief_title>
  <official_title>Vadadustat for the Prevention and Treatment of Acute Respiratory Distress Syndrome (ARDS) in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Akebia Therapeutics Inc.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The University of Texas Health Science Center, Houston</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy of vadadustat for the prevention and
      treatment of acute respiratory distress syndrome (ARDS) in hospitalized patients with
      Coronavirus Disease 2019 (COVID-19).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 22, 2020</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants who are classified 8 (dead), 7 (hospitalized, on invasive mechanical ventilation or ECMO), or 6 (hospitalized, on non-invasive ventilation or high flow oxygen devices) on the NIAID ordinal scale</measure>
    <time_frame>day 14</time_frame>
    <description>National Institute of Allergy and Infectious Disease Ordinal Scale (NIAID-OS):
8 - Death 7 - Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO) 6 - Hospitalized, on non-invasive ventilation or high flow oxygen devices 5 - Hospitalized, requiring supplemental oxygen 4 - Hospitalized, not requiring supplemental oxygen - requiring ongoing care (COVID-19 related or otherwise) 3 - Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care 2 - Not hospitalized, limitation on activities and/or requiring home oxygen
1 - Not hospitalized, no limitations on activities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with a total score of 0 on the Modified Sequential Organ Failure Assessment (MSOFA) scale</measure>
    <time_frame>day 14</time_frame>
    <description>Modified Sequential Organ Failure Assessment (MSOFA) scale:
Each of 5 organ systems is given a score of 0 to 4, as detailed below. The MSOFA scale total score is the sum of the score for the 5 organ systems. Discharged patients will be assigned a score of 0 and dead patients a score of 20.
Respiratory oxygen saturation(SpO2)/concentration of oxygen that a person inhales(FiO2): 0 (&gt; 400); 1 (≤ 400); 2 (≤ 315); 3 (≤ 235); 4 (≤ 150)
Liver: 0 (No scleral icterus or jaundice); 3 (Scleral icterus or jaundice)
Cardiovascular, hypotension: 0 (No hypotension); 1 (MAP &lt; 70 mm Hg); 2 (Dopamine ≤ 5 or dobutamine any dose); 3 (Dopamine &gt; 5, Epinephrine ≤ 0.1, Norepinephrine ≤ 0.1); 4 (Dopamine &gt; 15, Epinephrine &gt; 0.1, Norepinephrine &gt; 0.1)
Central Nervous System (CNS), Glasgow Coma Score: 0 (15), 1 (13 - 14); 2 (10 - 12); 3 (6 - 9); 4 (&lt; 6)
Renal, Creatinine mg/dL: 0 (&lt; 1.2); 1 (1.2 - 1.9); 2 (2.0 - 3.4); 3 (3.5 - 4.9); 4 (&gt; 5.0)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Respiratory Distress Syndrome</condition>
  <condition>Coronavirus Infection</condition>
  <arm_group>
    <arm_group_label>vadadustat</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vadadustat</intervention_name>
    <description>Participants will receive vadadustat once daily for 14 days.</description>
    <arm_group_label>vadadustat</arm_group_label>
    <other_name>AKB-6548</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Participants will receive matching placebo once daily for 14 days.</description>
    <arm_group_label>placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Laboratory-confirmed diagnosis of COVID-19 by detection of severe acute respiratory
             syndrome coronavirus 2 (SARS-CoV-2) RNA by Reverse transcription polymerase chain
             reaction (RT-PCR) from any specimen respiratory

          -  Admitted to the hospital

          -  Within 24 hours of hospital admission

          -  Oxygen saturation of hemoglobin by pulse oximetry at room air ≤94%

          -  Participation in any other clinical trial for the treatment for COVID-19 is not
             allowed

          -  Understands the procedures and requirements of the study and provides written informed
             consent and authorization for protected health information disclosure

        Exclusion Criteria:

          -  Males with hemoglobin &gt; 17.5 g/dl or females &gt;15.5 g/dl.

          -  Hypersensitivity to vadadustat or any of its excipients

          -  Placed on mechanical ventilation before randomization

          -  Hemoglobin above the gender-specific upper limit of normal (ULN) at randomization

          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), or total bilirubin
             &gt;2.0 x ULN at randomization

          -  Patients who have erythrocytosis or polycythemia vera

          -  Patient taking Probenecid as it can increase vadadustat exposure.

          -  Women who are pregnant or breastfeeding, or positive pregnancy test before
             randomization

          -  Patients on maintenance dialysis

          -  Patients who have received a solid organ transplant

          -  Patients who are prisoners

          -  Do Not Resuscitate (DNR)/Do Not Intubate (DNI) patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bentley J. Bobrow, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center, Houston</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bentley J. Bobrow, MD</last_name>
    <phone>713-500-7863</phone>
    <email>Bentley.J.Bobrow@uth.tmc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>The University of Texas Health Science Center at Houston</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bentley J. Bobrow, MD</last_name>
      <phone>713-500-7863</phone>
      <email>Bentley.J.Bobrow@uth.tmc.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 15, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2020</study_first_posted>
  <last_update_submitted>September 8, 2020</last_update_submitted>
  <last_update_submitted_qc>September 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center, Houston</investigator_affiliation>
    <investigator_full_name>Bentley J. Bobrow</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>ARDS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

